Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Published:2024-08 Issue: Volume:598 Page:217124
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Nakamura Ryota^ORCID,Yamada Tadaaki^ORCID,Tokuda Shinsaku^ORCID,Morimoto Kenji^ORCID,Katayama Yuki^ORCID,Matsui Yohei^ORCID,Hirai Soichi,Ishida Masaki,Kawachi Hayato,Sawada Ryo,Tachibana Yusuke,Osoegawa Atsushi^ORCID,Horinaka Mano^ORCID,Sakai Toshiyuki,Yasuhiro Tomoko,Kozaki Ryohei^ORCID,Yano Seiji,Takayama Koichi

Funder

Takeda Science Foundation

Princess Takamatsu Cancer Research Fund

Ono Pharmaceutical Co Ltd

Publisher

Elsevier BV

Reference43 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J. Clin.,2021

2. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis;Fujimoto;Clin. Exp. Metastasis,2014

3. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?;Han;Oncotarget,2016

4. EGFR mutation status on brain metastases from non-small cell lung cancer;Hsu;Lung Cancer,2016

5. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP